PRIMARY VISCERAL LEISHMANIASIS
Clinical trials for PRIMARY VISCERAL LEISHMANIASIS explained in plain language.
Never miss a new study
Get alerted when new PRIMARY VISCERAL LEISHMANIASIS trials appear
Sign up with your email to follow new studies for PRIMARY VISCERAL LEISHMANIASIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope against a deadly parasitic disease: LXE408 shows promise in phase II trial
Disease control CompletedThis study tested a new drug called LXE408 in 101 adults and teens with visceral leishmaniasis, a serious parasitic disease. Participants received one of two LXE408 doses or a standard treatment. The goal was to see if LXE408 could clear the parasite and improve symptoms by day 2…
Matched conditions: PRIMARY VISCERAL LEISHMANIASIS
Phase: PHASE2 • Sponsor: Drugs for Neglected Diseases • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New hope against a deadly parasite: LXE408 trial shows promise
Disease control CompletedThis study tested a new drug called LXE408 in 52 adults with visceral leishmaniasis, a serious parasitic disease. The goal was to see if LXE408 could cure the infection by Day 28 compared to the standard treatment. The trial took place in Ethiopia and measured safety, drug levels…
Matched conditions: PRIMARY VISCERAL LEISHMANIASIS
Phase: PHASE2 • Sponsor: Drugs for Neglected Diseases • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC